See more : Phoenix Tours International, Inc. (5706.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Drugs Limited (CONCORD.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Drugs Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Xiamen Lutong International Travel Agency Co. Ltd. (LTGJ) Income Statement Analysis – Financial Results
- IndoStar Capital Finance Limited (INDOSTAR.NS) Income Statement Analysis – Financial Results
- Pinnacle Minerals Limited (PIM.AX) Income Statement Analysis – Financial Results
- The Karur Vysya Bank Limited (KARURVYSYA.NS) Income Statement Analysis – Financial Results
- ArcWest Exploration Inc. (SJRNF) Income Statement Analysis – Financial Results
Concord Drugs Limited (CONCORD.BO)
About Concord Drugs Limited
Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. Its products include ready to fill pellets, mup's tissue bio adhesive, injectables, oral solid dosages, oral solid dosages, and liquid orals. The company was founded on April 24, 1995 and is headquartered in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 449.25M | 520.81M | 589.57M | 513.57M | 513.39M | 481.53M | 519.17M | 576.36M | 508.85M | 403.94M | 340.75M | 280.67M |
| Cost of Revenue | 332.54M | 410.30M | 421.37M | 430.72M | 427.02M | 399.79M | 435.24M | 464.24M | 390.44M | 314.21M | 294.80M | 246.79M |
| Gross Profit | 116.70M | 110.51M | 168.20M | 82.85M | 86.37M | 81.75M | 83.94M | 112.12M | 118.41M | 89.73M | 45.95M | 33.88M |
| Gross Profit Ratio | 25.98% | 21.22% | 28.53% | 16.13% | 16.82% | 16.98% | 16.17% | 19.45% | 23.27% | 22.21% | 13.48% | 12.07% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.69M | 2.06M | 2.27M | 2.33M | 1.70M | 25.29M | 19.74M | 28.07M | 16.14M | 6.16M | 10.66M | 9.20M |
| Selling & Marketing | 1.53M | 1.52M | 1.21M | 1.87M | 1.08M | 1.13M | 1.03M | 375.00K | 118.42K | 160.32K | 1.77M | 1.54M |
| SG&A | 3.22M | 3.58M | 3.48M | 4.20M | 2.78M | 26.43M | 20.77M | 28.44M | 16.26M | 6.32M | 12.43M | 10.74M |
| Other Expenses | 113.49M | 28.00K | 25.00K | 4.36K | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 116.70M | 79.96M | 76.60M | 62.87M | 67.57M | 61.71M | 59.80M | 83.84M | 63.53M | 52.56M | 24.40M | 18.29M |
| Cost & Expenses | 398.09M | 490.25M | 497.97M | 493.59M | 494.59M | 461.49M | 495.04M | 548.08M | 453.97M | 366.77M | 319.20M | 265.08M |
| Interest Income | 0.00 | 60.00K | 123.00K | 80.65K | 941.00K | 15.64M | 17.75M | 21.80M | 25.24M | 26.68M | 17.26M | 4.78M |
| Interest Expense | 18.68M | 17.28M | 16.77M | 13.31M | 14.46M | 15.71M | 17.82M | 24.25M | 25.25M | 26.68M | 17.81M | 0.00 |
| Depreciation & Amortization | 15.55M | 16.26M | 17.65M | 13.65M | 14.64M | 17.12M | 24.01M | 25.84M | 29.12M | 36.28M | 11.43M | 7.17M |
| EBITDA | 40.52M | 45.81M | 56.79M | 32.83M | 34.32M | 37.35M | 49.08M | 56.52M | 84.96M | 73.94M | 33.51M | 23.14M |
| EBITDA Ratio | 9.02% | 8.87% | 18.38% | 6.39% | 6.51% | 7.76% | 9.45% | 9.81% | 16.70% | 18.30% | 9.84% | 8.25% |
| Operating Income | 51.15M | 29.46M | 39.14M | 19.41M | 19.68M | 20.23M | 25.07M | 30.68M | 55.84M | 37.66M | 22.09M | 15.97M |
| Operating Income Ratio | 11.39% | 5.66% | 6.64% | 3.78% | 3.83% | 4.20% | 4.83% | 5.32% | 10.97% | 9.32% | 6.48% | 5.69% |
| Total Other Income/Expenses | -44.87M | -43.17M | -41.85M | 146.69K | -14.24M | -20.49M | -15.83M | -77.21M | -26.21M | -27.16M | -29.23M | -5.16M |
| Income Before Tax | 6.29M | 12.49M | 22.48M | 42.92M | 4.57M | 4.40M | 6.39M | 6.47M | 29.63M | 10.49M | 4.28M | 10.81M |
| Income Before Tax Ratio | 1.40% | 2.40% | 3.81% | 8.36% | 0.89% | 0.91% | 1.23% | 1.12% | 5.82% | 2.60% | 1.26% | 3.85% |
| Income Tax Expense | 1.57M | 2.63M | 6.54M | 10.10M | 1.28M | 328.00K | 3.15M | 4.88M | 12.15M | 3.53M | 896.90K | 400.84K |
| Net Income | 4.72M | 9.86M | 15.94M | 32.82M | 3.28M | 4.07M | 3.24M | 1.60M | 17.48M | 6.96M | 3.39M | 10.41M |
| Net Income Ratio | 1.05% | 1.89% | 2.70% | 6.39% | 0.64% | 0.85% | 0.62% | 0.28% | 3.44% | 1.72% | 0.99% | 3.71% |
| EPS | 0.47 | 1.06 | 1.82 | 3.75 | 0.38 | 0.52 | 0.41 | 0.22 | 2.41 | 0.96 | 0.47 | 1.44 |
| EPS Diluted | 0.47 | 1.06 | 1.82 | 3.75 | 0.38 | 0.52 | 0.41 | 0.22 | 2.41 | 0.96 | 0.47 | 1.44 |
| Weighted Avg Shares Out | 10.05M | 9.32M | 8.74M | 8.74M | 8.74M | 7.86M | 7.90M | 7.25M | 7.26M | 7.25M | 7.24M | 7.24M |
| Weighted Avg Shares Out (Dil) | 10.05M | 9.32M | 8.74M | 8.74M | 8.74M | 7.86M | 7.86M | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M |
Source: https://incomestatements.info
Category: Stock Reports